Intracranial responses with selective KRAS-G12C inhibitors in non-small cell lung cancer

被引：1
|
作者：
Lu, Kevin [1 ]
Husain, Hatim [1 ,2 ]
机构：
[1] Univ Calif San Diego, La Jolla, CA USA
[2] Univ Calif San Diego, Div Med Oncol, 3855 Hlth Sci 3011, La Jolla, CA 92093 USA
来源：
TRANSLATIONAL LUNG CANCER RESEARCH | 2023年 / 12卷 / 06期
关键词：
Non-small cell lung cancer (NSCLC); KRAS G12C; adagrasib; sotorasib; BRAIN METASTASES; NSCLC;
D O I：
10.21037/tlcr-23-26
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1335 / 1337
页数：3
相关论文
共 50 条
  • [1] Role of AXL activation on adaptive resistance to KRAS-G12C inhibitors in KRAS-G12C-mutated non-small cell lung cancer
    Yamada, T.
    Morimoto, K.
    Hirai, S.
    Katayama, Y.
    Kunimasa, K.
    Sasaki, T.
    Nishida, M.
    Watanabe, S.
    Shiotsu, S.
    Uehara, H.
    Takayama, K.
    ANNALS OF ONCOLOGY, 2023, 34 : S194 - S194
  • [2] KRAS-G12C mutation in non-small cell lung cancer: prevalence and prognostic significance
    Cristobal Redondo, V.
    Pedrero Castillo, V.
    Parra Trujillo, D.
    Alenda Gonzalez, C.
    Aranda Lopez, F. I.
    VIRCHOWS ARCHIV, 2022, 481 (SUPPL 1) : S146 - S147
  • [3] Ornithine decarboxylase as a new target for improving the effect of KRAS-G12C inhibitors in non-small cell lung cancer cells
    Martin, A.
    Buelvas, N.
    Guzman, C.
    Guzman, S.
    Mansilla, M.
    Munoz, R. Lopez
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S60 - S61
  • [4] AXL activation promotes adaptive resistance to KRAS-G12C inhibitors in KRASG12C-mutated non-small cell lung cancer
    Morimoto, Kenji
    Yamada, Tadaaki
    Hirai, Soichi
    Katayama, Yuki
    Kunimasa, Kei
    Sasaki, Takaaki
    Nishida, Makoto
    Watanabe, Satoshi
    Shiotsu, Shinsuke
    Uehara, Hisanori
    Takayama, Koichi
    CANCER RESEARCH, 2024, 84 (06)
  • [5] Tissue factor overexpression promotes resistance to KRAS-G12C inhibition in non-small cell lung cancer
    Zhang, Yu
    Liu, Liang
    Pei, Jinpeng
    Ren, Zhiqiang
    Deng, Yan
    Yu, Ker
    ONCOGENE, 2024, 43 (09) : 668 - 681
  • [6] Tissue factor overexpression promotes resistance to KRAS-G12C inhibition in non-small cell lung cancer
    Yu Zhang
    Liang Liu
    Jinpeng Pei
    Zhiqiang Ren
    Yan Deng
    Ker Yu
    Oncogene, 2024, 43 : 668 - 681
  • [7] KRAS G12C mutations in non-small cell lung cancer
    Li, J. J.
    Wu, X. J.
    Farzin, M.
    Bray, V.
    Williamson, J.
    Pal, A.
    Yip, P. Y.
    Hagelamin, A.
    Ding, P.
    Nindra, U.
    Vinod, S.
    French, B.
    Chua, W.
    Gupta, R.
    Cooper, W. A.
    Wang, B.
    Lee, C. S.
    HISTOPATHOLOGY, 2024, 85 : 25 - 25
  • [8] Anlotinib enhances the efficacy of KRAS-G12C inhibitors through c-Myc/ORC2 axis inhibition in non-small cell lung cancer
    Hongyu Liu
    Chao Zhou
    Jun Lu
    Yuqing Liu
    Peichen Zou
    Liang Zhu
    Huimin Lei
    Baohui Han
    Cell Death & Disease, 16 (1)
  • [9] Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes
    Palma, Gabriela
    Khurshid, Faisal
    Lu, Kevin
    Woodward, Brian
    Husain, Hatim
    NPJ PRECISION ONCOLOGY, 2021, 5 (01)
  • [10] Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes
    Gabriela Palma
    Faisal Khurshid
    Kevin Lu
    Brian Woodward
    Hatim Husain
    npj Precision Oncology, 5
12345